BetterLife Pharma Inc. (BETR.CN)
CAD 0.09
(-5.26%)
CAD 0.09
(-5.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.24 Million CAD | -65.0% |
| 2022 | 9.25 Million CAD | -7.14% |
| 2021 | 9.96 Million CAD | 25.33% |
| 2020 | 7.95 Million CAD | -13.52% |
| 2019 | 9.19 Million CAD | 64.45% |
| 2018 | 5.59 Million CAD | 382.81% |
| 2017 | 1.15 Million CAD | -84.83% |
| 2016 | 7.63 Million CAD | -36.3% |
| 2015 | 11.99 Million CAD | 16583.09% |
| 2014 | 71.87 Thousand CAD | 56.74% |
| 2013 | 45.85 Thousand CAD | -48.87% |
| 2012 | 89.69 Thousand CAD | -75.01% |
| 2011 | 358.97 Thousand CAD | 152.4% |
| 2010 | 142.22 Thousand CAD | 19.55% |
| 2009 | 118.96 Thousand CAD | -22.37% |
| 2008 | 153.23 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.26 Million CAD | 210.48% |
| 2024 Q2 | 1.11 Million CAD | -48.45% |
| 2023 Q3 | 698.62 Thousand CAD | -31.14% |
| 2023 Q2 | 1.01 Million CAD | 32.37% |
| 2023 Q1 | 766.44 Thousand CAD | -5.1% |
| 2023 Q4 | 730.24 Thousand CAD | 4.53% |
| 2023 FY | 3.2 Million CAD | -65.33% |
| 2022 Q4 | 807.65 Thousand CAD | -81.42% |
| 2022 Q1 | 3.02 Million CAD | 41.76% |
| 2022 Q2 | 1.21 Million CAD | -59.95% |
| 2022 Q3 | 4.34 Million CAD | 259.14% |
| 2022 FY | 9.25 Million CAD | -7.14% |
| 2021 Q2 | 3.36 Million CAD | 41.74% |
| 2021 FY | 9.96 Million CAD | 25.33% |
| 2021 Q1 | 2.37 Million CAD | 2.67% |
| 2021 Q3 | 2.1 Million CAD | -37.35% |
| 2021 Q4 | 2.13 Million CAD | 1.22% |
| 2020 Q2 | 1.5 Million CAD | 31.21% |
| 2020 Q1 | 1.14 Million CAD | 2.74% |
| 2020 Q4 | 2.3 Million CAD | -17.33% |
| 2020 FY | 7.95 Million CAD | -13.52% |
| 2020 Q3 | 2.79 Million CAD | 85.23% |
| 2019 FY | 9.19 Million CAD | 64.45% |
| 2019 Q1 | 1.67 Million CAD | 34.48% |
| 2019 Q4 | 1.11 Million CAD | -51.4% |
| 2019 Q3 | 2.3 Million CAD | -43.76% |
| 2019 Q2 | 4.09 Million CAD | 144.51% |
| 2018 Q2 | 1.51 Million CAD | -17.93% |
| 2018 Q1 | 1.84 Million CAD | 402.86% |
| 2018 Q4 | 1.24 Million CAD | -31.3% |
| 2018 Q3 | 1.81 Million CAD | 19.9% |
| 2018 FY | 5.59 Million CAD | 382.81% |
| 2017 Q1 | 293.9 Thousand CAD | -65.25% |
| 2017 FY | 1.15 Million CAD | -84.83% |
| 2017 Q4 | 366.17 Thousand CAD | 95.64% |
| 2017 Q3 | 187.17 Thousand CAD | -41.41% |
| 2017 Q2 | 319.47 Thousand CAD | 8.7% |
| 2016 Q2 | 1.45 Million CAD | -64.99% |
| 2016 Q3 | 844.7 Thousand CAD | -42.07% |
| 2016 FY | 7.63 Million CAD | -36.3% |
| 2016 Q4 | 845.68 Thousand CAD | 0.12% |
| 2016 Q1 | 4.16 Million CAD | -45.21% |
| 2015 Q4 | 7.6 Million CAD | 166121.71% |
| 2015 FY | 11.99 Million CAD | 16583.09% |
| 2015 Q2 | 2.94 Million CAD | 103.45% |
| 2015 Q1 | 1.44 Million CAD | 10285.68% |
| 2015 Q3 | 4573.00 CAD | -99.84% |
| 2014 Q2 | 29.84 Thousand CAD | 160.36% |
| 2014 Q1 | 11.46 Thousand CAD | 215.95% |
| 2014 FY | 71.87 Thousand CAD | 56.74% |
| 2014 Q4 | 13.91 Thousand CAD | -16.47% |
| 2014 Q3 | 16.65 Thousand CAD | -44.18% |
| 2013 Q4 | -9885.00 CAD | -157.92% |
| 2013 Q2 | 27.31 Thousand CAD | 140.33% |
| 2013 Q3 | 17.06 Thousand CAD | -37.51% |
| 2013 Q1 | 11.36 Thousand CAD | 392.28% |
| 2013 FY | 45.85 Thousand CAD | -48.87% |
| 2012 Q4 | -3888.00 CAD | -115.57% |
| 2012 FY | 89.69 Thousand CAD | -75.01% |
| 2012 Q1 | 37 Thousand CAD | 187.82% |
| 2012 Q2 | 31.59 Thousand CAD | -14.62% |
| 2012 Q3 | 24.97 Thousand CAD | -20.96% |
| 2011 Q1 | 177.57 Thousand CAD | 238.45% |
| 2011 Q3 | 154.36 Thousand CAD | 110.45% |
| 2011 Q4 | -42.14 Thousand CAD | -127.3% |
| 2011 FY | 358.97 Thousand CAD | 152.4% |
| 2011 Q2 | 73.35 Thousand CAD | -58.69% |
| 2010 Q2 | 42.52 Thousand CAD | 57.19% |
| 2010 Q1 | 27.05 Thousand CAD | 68.16% |
| 2010 Q4 | 52.46 Thousand CAD | 159.92% |
| 2010 FY | 142.22 Thousand CAD | 19.55% |
| 2010 Q3 | 20.18 Thousand CAD | -52.53% |
| 2009 Q2 | 75.96 Thousand CAD | 493.3% |
| 2009 Q3 | 14.11 Thousand CAD | -81.42% |
| 2009 FY | 118.96 Thousand CAD | -22.37% |
| 2009 Q4 | 16.08 Thousand CAD | 13.96% |
| 2009 Q1 | 12.8 Thousand CAD | 0.0% |
| 2008 FY | 153.23 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 5.19 Million CAD | 37.587% |
| Asep Medical Holdings Inc | 7.74 Million CAD | 58.149% |
| BioVaxys Technology Corp. | 2.4 Million CAD | -34.864% |
| ChitogenX Inc. | 2.83 Million CAD | -14.496% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | 23.006% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 74.397% |
| Entheon Biomedical Corp. | 564.31 Thousand CAD | -474.19% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | 36.29% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -12500.587% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | -380.236% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | -166.238% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -4394.903% |
| MYND Life Sciences Inc. | 1.47 Million CAD | -119.709% |
| Nova Mentis Life Science Corp. | 1.2 Million CAD | -169.504% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | -6.444% |
| PreveCeutical Medical Inc. | 963.12 Thousand CAD | -236.43% |
| Telescope Innovations Corp. | 6.35 Million CAD | 48.991% |